

REVIEW ARTICLE



## Mitochondrial dysfunction in protein conformational disorders

SHLOMI BRIELLE<sup>2\*</sup> and DANIEL KAGANOVICH<sup>1,2\*</sup> 

<sup>1</sup>Department of Experimental Neurodegeneration, University Medical Center Gottingen, Waldweg 33, Göttingen, Germany

<sup>2</sup>Department of Cell and Developmental Biology, Hebrew University of Jerusalem, Givat Ram, Jerusalem, Israel

\*For correspondence. E-mail: Shlomi Brielle, shlomi.brielle@mail.huji.ac.il; Daniel Kaganovich, dan@cc.huji.ac.il.

Received 7 January 2018; revised 22 March 2018; accepted 3 April 2018

**Abstract.** Protein aggregation is a hallmark of many neurodegenerative diseases. In Parkinson's disease protein misfolding of  $\alpha$ -synuclein involves conformational changes in the protein structure that often results in self-association and aggregation leading to accumulation of  $\alpha$ -synuclein in neuronal cells. The underlying mechanisms by which aggregations can lead to impaired cellular functions are often not understood. Meanwhile, there is growing evidence that links mitochondrial dysfunction to Parkinson's disease. As both mitochondria and protein aggregation of  $\alpha$ -synuclein have been shown to play a major role in Parkinson's disease, it seems likely that a converging mechanism exists that links the two pathways.

**Keywords.** mitochondria; Parkinson's disease;  $\alpha$ -synuclein; ageing; neurodegene.

### Introduction

Parkinson's disease (PD), a degenerative disorder of the central nervous system is characterized by the loss of dopaminergic neurons, and the presence of large protein inclusion bodies termed Lewy bodies. Although neither dopaminergic neuron loss nor the appearance of Lewy bodies are phenomena that are unique to PD, together they suffice for diagnosis of idiopathic PD (Poewe *et al.* 2017). The loss of dopaminergic neuronal cells can occur prior to the appearance of Lewy bodies (Dijkstra *et al.* 2014) and results in dopamine deficiency in the central nervous system. Notable loss in neurons (>50%), even in early stages of the disease is suggested to precede impaired communication between muscles and the brain that leads to manifestations of motor symptoms (Poewe *et al.* 2017; Cheng *et al.* 2010; Dauer and Przedborski 2003).

Protein folding is essential to cellular function. The disruption of protein-folding homeostasis leads to misfolding and can result in proteins that oligomerize and accumulate, inducing cytotoxic effects (Kaganovich 2017; Brielle *et al.* 2015; Kaganovich *et al.* 2008). Aggregation of proteins is associated with an increasing number of neurodegenerative diseases such as Alzheimer disease (AD), PD, Huntington disease (HD) and Amyotrophic lateral sclerosis (ALS). In PD's point mutation and

multiplications of synuclein alpha (*SNCA*), the gene that encodes  $\alpha$ -synuclein results in gain of function and cytosolic accumulation, and aggregation into large deposits called Lewy bodies. It is not entirely clear how  $\alpha$ -synuclein aggregation is linked to neuronal degeneration and if  $\alpha$ -synuclein misfolding is a cause or a byproduct of PD pathology, however the emerging paradigm suggests that misfolded monomers and low molecular weight oligomers of  $\alpha$ -synuclein are cytotoxic (Lashuel *et al.* 2013), while larger inclusion bodies that appear in late stages of the disease may play a protective role in cellular function (Tanaka *et al.* 2004). By sequestering reactive, often hydrophobic, misfolded proteins to specialized cellular compartments, cells can restrict their interaction with other proteins, membranes and organelles. Further, in response to accumulation of misfolded proteins, cells relocate quality control machinery, such as molecular chaperones and proteases, to inclusions bodies allowing cells to efficiently process misfolded and aggregated proteins (Dijkstra *et al.* 2014; Kaganovich *et al.* 2008).

### $\alpha$ -Synuclein

*SNCA* is the first gene to be associated with hereditary PD, although pathogenic mutations in *SNCA* are responsible for only a small fraction of cases of hereditary PD

(Farrer *et al.* 1998). Yet the discovery of these mutations was a stepping stone in unravelling the molecular pathways associated with PD and establishing  $\alpha$ -synuclein's role in both hereditary and sporadic forms of PD. The first evidence linking  $\alpha$ -synuclein to PD was obtained with the discovery of familial missense mutation A53T, in the gene *SNCA* that was responsible for the disease onset in families with autosomal dominant inheritance of PD (Polymeropoulos *et al.* 1996, 1997; Krüger *et al.* 1998; Nussbaum 2017). This identification pathogenic *SNCA* mutation has led to the discovery of several other disease-related mutations: A30P, E46K, G51D, and H50Q in *SNCA* (Krüger *et al.* 1998; Zarranz *et al.* 2004; Lesage *et al.* 2013; Appel-Cresswell *et al.* 2013).

Shortly after the identification of *SNCA* mutations in hereditary PD, it was found that  $\alpha$ -synuclein is one the main components of Lewy bodies in idiopathic PD (Spillantini *et al.* 1997). Since the detection of  $\alpha$ -synuclein in Lewy bodies, there is a growing interest in molecular mechanisms that link  $\alpha$ -synuclein, Parkinson and protein aggregation and numerous works that studied the cytotoxic effects of  $\alpha$ -synuclein's aggregation. Early studies in  $\alpha$ -synuclein's aggregation properties demonstrated that expression of both wild type and mutant human  $\alpha$ -synuclein in transgenic mice leads to the progressive accumulation of  $\alpha$ -synuclein in cytoplasmic inclusions in neuronal cells in the neocortex, hippocampus, and substantia nigra (Masliah *et al.* 2000; Breydo *et al.* 2012). The appearance of these inclusions was associated with loss of dopaminergic neurons and loss motor functions. Similar results were also been reported in a *Drosophila* Parkinson model and in *Caenorhabditis elegans* expressing mutant  $\alpha$ -synuclein (Feany and Bender 2000; Kuwahara *et al.* 2006). In accordance with these results, there have been numerous studies reporting that expression of mutant  $\alpha$ -synuclein in cell culture models, results in the formation of oligomers and amyloid fibrils including a systemic comparison of the aggregation properties of different  $\alpha$ -synuclein mutations in cell culture models (Lázaro *et al.* 2014).

The molecular mechanisms that leads to the formation of oligomers and amyloid fibrils have been studied extensively both *in vitro* and *in vivo*.  $\alpha$ -Synuclein is considered as an intrinsically disordered protein which possesses no ordered structure under physiological conditions and therefore has striking conformational plasticity under various conditions (Uversky 2007). *In vitro*  $\alpha$ -synuclein can adopt various conformations including: unfolded native state,  $\alpha$ -helical and  $\beta$ -sheet species that can include both monomeric and oligomeric states as well as amorphous aggregates and amyloid-like fibrils (Breydo *et al.* 2012). *In vitro* studies into the aggregation kinetics of  $\alpha$ -synuclein have demonstrated that the formation of  $\alpha$ -synuclein fibrils are nucleation dependent. Further, the induction of fibril formation by aggregated  $\alpha$ -synuclein appears to follow first order kinetics with respect to the

concentration of  $\alpha$ -synuclein. Interestingly, incubation of wild-type  $\alpha$ -synuclein with mutant  $\alpha$ -synuclein nuclei results in the induction of wild-type  $\alpha$ -synuclein aggregation (Wood *et al.* 1999), suggesting that  $\alpha$ -synuclein aggregation is promoted by a process of template seeding. Indeed, in a more recent study, it was demonstrated that neuronal cells can form inclusion after being cocultured with neuronal cells overexpressing  $\alpha$ -synuclein (Desplats *et al.* 2009).

Although the question of how of  $\alpha$ -synuclein different aggregates species exert neurotoxicity is still under debate, the current paradigm suggests that oligomeric intermediates of  $\alpha$ -synuclein are responsible for cytotoxicity rather than large inclusion or amyloid-like fibrils. *In vitro* studies of the aggregation dynamics of the pathogenic  $\alpha$ -synuclein A30P have shown that while this mutant form of  $\alpha$ -synuclein inhibits the formation of the fibrillar  $\alpha$ -synuclein compared to wild-type  $\alpha$ -synuclein, the formation of oligomeric species of  $\alpha$ -synuclein is slightly accelerated. Similarly, the pathogenic  $\alpha$ -synuclein A53T was also demonstrated to accelerate the formation of oligomeric species, however in this case, it accelerated the formation of fibrillar  $\alpha$ -synuclein. Together, these results suggest that pathogenic mutants of  $\alpha$ -synuclein promote the formation of oligomers rather than fibrils (Conway *et al.* 2000). The toxicity of oligomeric  $\alpha$ -synuclein has also been demonstrated in several cell culture models. In primary neuronal cells, that were exposed to samples containing different  $\alpha$ -synuclein species, cells exposed to oligomeric but not monomeric or fibril  $\alpha$ -synuclein showed increased oxidative stress (Cremades *et al.* 2012). In addition, a systemic comparison of the effects of  $\alpha$ -synuclein mutations on oligomerization and aggregation in cell culture showed that familial mutants linked to PD have similar propensities to form oligomers yet differ in their propensities to form aggregates (Lázaro *et al.* 2014).

### Structure and functions of $\alpha$ -synuclein

There are currently three known proteins belonging to the synuclein family:  $\alpha$ -synuclein,  $\beta$ -synuclein, and  $\gamma$ -synuclein. All proteins belonging to this family contain a highly conserved lipid-binding domain that is found only in vertebrates and have some similarity to the binding motif of apolipoprotein A<sub>2</sub>, a class of protein that can reversibly bind and transport lipids (Eliezer *et al.* 2001; Jo *et al.* 2000).  $\alpha$ -Synuclein which is best known for its association PD is composed of only 140 amino acids: the membrane-binding domain of  $\alpha$ -synuclein is located in the N-terminus section (1–95), which contains seven segments each 11-residues in length. Each of the seven segments in the N-terminus section contains a repeating consensus sequence KTKEGV (Ulmer *et al.* 2005). In aqueous solution, the N-terminus of  $\alpha$ -synuclein is considered to be intrinsically disordered but upon

association with a membrane surface it can adopt a helical form with an 11/3 periodicity (11 residues over three turns). Located in the central region of  $\alpha$ -synuclein (61–95), and overlapping with the N-terminus  $\alpha$ -helix, is a highly hydrophobic segment of 35 residues termed the nonA $\beta$  component (NAC). Interestingly, this hydrophobic section of  $\alpha$ -synuclein was reported to be abundant in plaques associated with AD. Finally, the C-terminus of  $\alpha$ -synuclein is considered unstructured and is enriched with acidic residues glutamate and aspartate. Recently, C-terminus truncated forms of  $\alpha$ -synuclein were reported to be enriched in  $\alpha$ -synuclein inclusions and may enhance the aggregation of full-length  $\alpha$ -synuclein (Lashuel *et al.* 2013).

The function of  $\alpha$ -synuclein under normal physiological conditions is not well understood yet its abundance in presynaptic terminals of neuronal cells would suggest its involvement in synaptic maintenance. Several works have shown that overexpression of  $\alpha$ -synuclein in transgenic mice can cause functional defects in the handling of the synaptic vesicles such as inhibition of synaptic vesicle exocytosis (Burré 2015; Bendor *et al.* 2013; Nemani *et al.* 2010). In addition, some studies that examined neuronal cells of  $\alpha$ -synuclein knockout mice have suggested that  $\alpha$ -synuclein may inhibit dopamine synaptic release in neuronal cells (Cabin *et al.* 2002) and that increase in the rate of dopamine release may decrease the stores of dopamine in the striatum of knockout mice (Abeliovich *et al.* 2000). In accordance with these studies, it was reported that hippocampal neurons from  $\alpha$ -synuclein knockout mice have a significant reduction ( $\sim 50\%$ ) in undocked synaptic vesicles but the same number of docked vesicles in the presynaptic terminal of neurons compared to wild-type mice (Murphy *et al.* 2000). Taken together, these findings suggest that  $\alpha$ -synuclein has a role in regulating and upkeep of synaptic vesicles. Other studies in support of  $\alpha$ -synuclein role in the synaptic dynamics have shown that synucleins are required for maintenance of presynaptic SNARE-complex, specifically,  $\alpha$ -synuclein was reported to bind to the SNARE protein synaptobrevin-2/vesicle-associated membrane protein 2 (VAMP2) and promoted the assembly of the SNARE-complex (Burré *et al.* 2010).  $\alpha$ -Synuclein was also implicated in the inhibition of phospholipase D2 (PLD2), an enzyme responsible for catalysing the hydrolysis of phosphatidylcholine (PC) to phosphatidic acid, a precursor for the biosynthesis of many cellular lipids. Phosphatidic acid is also essential for inducing membrane curvature and vesicle budding. It has been proposed that mutation in  $\alpha$ -synuclein could influence the regulation of PLD2 and interfere with synaptic membrane biogenesis and turnover (Payton *et al.* 2004).

### Membrane interactions of $\alpha$ -synuclein

Although  $\alpha$ -synuclein is a soluble cytosolic protein, it is known to bind a variety of cellular membranes. The N-terminus of  $\alpha$ -synuclein forms an amphiphilic  $\alpha$ -helix that

can associate with negatively charged membranes (Davidson *et al.* 1998; Pineda and Burré 2017). Amphiphilic  $\alpha$ -helices are common in membrane-binding proteins as they energetically favour the hydrophilic–hydrophilic interface of membranes due to the hydrophobic effect (Khandelia *et al.* 2008). In addition, in case of  $\alpha$ -synuclein electrostatic, interactions exist between positively charged lysine residues within the helix structure and negatively charged lipid head groups that can stabilize the association of  $\alpha$ -synuclein with membrane surfaces. Because of their asymmetrical segregation to hydrophobic and hydrophilic faces, amphiphilic  $\alpha$ -helices tend to aggregate in aqueous solution. Indeed, deletion of a 12 amino acid section within the amphiphilic  $\alpha$ -helix in the hydrophobic stretch of the NAC abrogates the ability of  $\alpha$ -synuclein to aggregate (Giasson *et al.* 2001). In accordance with these results, all identified familial mutations in  $\alpha$ -synuclein (A30P, E46K, A53T, G51D and H50Q) reside within the amphiphilic  $\alpha$ -helix region (Lázaro *et al.* 2014). Further, as aggregation kinetics is often a function of expression level, it is interesting to note that increased expression of  $\alpha$ -synuclein in patients with *SNCA* triplication results in early-onset Parkinsonism (Singleton *et al.* 2003) whereas patients with locus duplication results in a late onset. Although *SNCA* duplications are not a common cause of PD (Johnson *et al.* 2004) the study of *SNCA* multiplication indicated that  $\alpha$ -synuclein pathogenesis is dosage dependent and that increased expression levels of  $\alpha$ -synuclein can accelerate pathogenesis (Farrer *et al.* 2004).

It is interesting to note that  $\alpha$ -synuclein preferentially binds to small liposomes (20–25  $\mu\text{m}$ ) rather than larger liposomes and also membranes that contain packing defects (Davidson *et al.* 1998; Drin and Antonny 2010). Due to its ability to bind liposomes based on size,  $\alpha$ -synuclein is classified as a membrane curvature sensor. The ability to selectively bind vesicles with small curvature might be related to  $\alpha$ -synuclein localization to synaptic vesicles (Drin and Antonny 2010). It is also important to note that while the association of  $\alpha$ -synuclein with membranes might be related to its endogenous function, it might also drastically affect its tendency to oligomerize by locally increasing the concentration of  $\alpha$ -synuclein in the vicinity of membranes. Further, due to  $\alpha$ -synuclein inclination to oligomerize, and because of its favourable association with membranes, it is likely that  $\alpha$ -synuclein has a role in membrane remodelling.

### Mitochondrial dysfunction in PD

By producing energy (ATP) mitochondria plays an essential role in all cell types. Besides energy production, mitochondria also plays a major role in variety of other cellular functions, such as the regulation of the intrinsic pathway of apoptosis, ion buffering, metabolism of lipids and production and regulation of reactive oxygen species (ROS). Mitochondrial impairment is often characterized

by a number of damaging effects such as impaired oxidative phosphorylation that leads to decreased levels of ATP, an increase in the production of reactive oxygen species that can lead to a state of oxidative stress and cytochrome *c* leakage which can lead to apoptosis. All of which can have deleterious effect on cellular functions and even more so in the nervous system where metabolic requirements are more demanding. The constantly changing flux of  $\text{Ca}^{+2}$  that is crucial to maintaining neuronal excitability as well as the production and shipment of neurotransmitter vesicles are responsible alone for about 20% of the human body energy consumption (Kann and Kovács 2007). Further, neuronal cells that can span up to 1 m in length require efficient and highly dynamic transport of energy as well as metabolites (Hollenbeck 2005). With an increased rate of energy production postmeiotic neuronal cells must also tightly regulate the production and maintenance of reactive oxygen species which are a byproduct of oxidative phosphorylation and can lead to oxidative stress.

In almost all cell types, mitochondria forms a highly connected and dynamic tubular network that rapidly cycles between mitochondrial fusion and fission (Schrepfer and Scorrano 2016; Westermann 2010). Mitochondrial fusion and fission are both extremely important for mitochondrial fidelity and function: mitochondrial fission enables the proper radial distribution of the mitochondrial network in cells as well as the distribution of mitochondrial DNA in the mitochondrial network. Mitochondrial fission is also critical for the isolation and clearance of damaged mitochondria. Mitochondrial fission is mediated by Drp1, a dynamin related GTPase. Drp1 is a profission protein which is able to form constricting rings on the surface of the outer mitochondrial membrane by GTP hydrolysis. The rings apply mechanical strain on both the outer and inner membranes allowing the tubular mitochondria to separate (Westermann 2010; Smirnova *et al.* 1998). Mitochondrial fusion, on the other hand, e.g. is used for complementation of mitochondrial proteins. As mitochondrial DNA can become damaged over time, mutated mitochondrial genes can lead to respiratory dysfunction; mitochondrial complementation increases the fidelity of aged mitochondria by exchanging proteins products between damaged and healthy mitochondria. The mechanism of mitochondrial fusion requires two homologue GTP-binding proteins to fuse the outer mitochondrial membranes: mitofusin 1 (MFN1) and mitofusin 2 (MFN2) while optic atrophy 1 (OPA1), a Dynamin-like protein, is required for fusion of the inner membrane of the mitochondria (Chen *et al.* 2003). The regulation of mitochondrial fusion and fission by direct interaction with the mitochondria or with the fusion or fission machinery is tightly linked to many mitochondrial functions and pathways. Consequently, mitochondrial morphology in neuronal cells is central to the pathogenesis of many neurodegenerative disorders (Lin and Beal 2006; Burté *et al.* 2015).

### Toxin-based mitochondrial dysfunction associated with PD

The first evidence linking mitochondrial dysfunction and PD came to focus in the late seventies when accidental exposure to a material called 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a byproduct of an illicit drug 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP), resulted in four people developing features strikingly similar to Parkinson (Langston *et al.* 1983). An autopsy later revealed these patients displayed degeneration of dopaminergic neurons but without the presence of Lewy bodies. Subsequently, it was found that the onset of their symptoms was caused by the inhibition of complex I of the mitochondrial respiratory chain in dopaminergic neurons (Nicklas *et al.* 1987; Dauer and Przedborski 2003). Since then a number of mitochondria inhibitors such as rotenone and 6-OHDA have been reported to induce Parkinson-like symptoms in animal models (Betarbet *et al.* 2000). Although the death of neuronal cells is not only restricted to dopaminergic neurons, it has been suggested that catecholamine-secreting neurons are more susceptible to mitochondrial dysfunction as the production of dopamine is an additional source for the production of reactive oxygen species.

### Mitochondrial functions of genes associated with PD

Tough only 5–10% of Parkinson patients carry a heritable form of PD, the identification of the pathogenic genes associated with PD have provided crucial clues to the pathways involved in idiopathic PD. Specific mutation in more than 10 genes so far has been associated with the familial form of PD including: of interest, mutations in the genes that encode PINK1, Parkin, and DJ-1 that result in autosomal recessive Parkinsonism, and mutations in the genes encoding leucine-rich repeat kinase 2 (*LRRK2*),  $\alpha$ -synuclein (*SNCA*) and the recently identified: vacuolar protein sorting 35 (*VPS35*) cause the onset of the dominant form of PD (Trinh 2013; Farrer 2006). Of special interest in recent years are the genes: *LRRK2*, mutations in this gene are present in 13% of familial dominant inheritance PD cases and are responsible for up to 50% of all cases in some population (Farrer 2006), the genes that encode PINK1 and Parkin, two mitochondrial proteins that participate in autophagosomal clearance of dysfunctional mitochondria (Pickrell and Youle 2015), and DJ-1 which has been suggested to have a role as a sensor for oxidative stress and has been shown to act as a chaperone that prevents the aggregation of  $\alpha$ -synuclein (Zhou *et al.* 2006).

#### *PARKIN and PINK1*

In recent years multiple findings have linked the disruption of mitochondrial dynamics to neurodegenerative

disorders. In Parkinson, multiple pathways and proteins (table 1) associated with the disease have been implicated in modulating mitochondria morphology, autophagy, and fission or fusion of mitochondria (Poole *et al.* 2008; Michel *et al.* 2016; Bertholet *et al.* 2016). Both PINK1 and Parkin which are associated with autosomal recessive PD contribute to the mitochondria quality control by regulating the removal of dysfunctional mitochondria by mitophagy (Narendra *et al.* 2008; Pickrell and Youle 2015). Under normal physiological conditions, PINK1 is imported into the inner mitochondrial membrane by the mitochondrial import complexes TOM and TIM. Following the import of PINK1, a protease protein, presenilin-associated rhomboid-like protein (PARL) attaches to PINK1 and cleaves its N-terminus section. The truncated form of PINK1 is then released into the cytosol where it degraded by the proteasome system. As a consequence of the continuous importation and degradation of PINK1 under normal conditions, PINK1 levels on the outer mitochondrial membrane are maintained relatively low. In response to mitochondrial stress, protein import through the TOM complex is less efficient or blocked and therefore PARL cannot cleave PINK1 which accumulates on the outer mitochondrial membrane. The accumulation of PINK1 signals the cytosolic E3 ubiquitin-protein ligase, Parkin to ubiquitinate a wide range of mitochondrial and cytoplasmic (Yamano and Youle 2013; Jin *et al.* 2010). More than 36 proteins on the outer mitochondrial membrane are subjected to ubiquitination and are later degraded by the proteasome pathway (Chan *et al.* 2011). The removal and degradation of mitochondrial proteins appears to be necessary for mitophagy, however the signal for mitophagy might not be substrate specific but instead dependent on the density and the type of ubiquitin chains that Parkin attaches (Sarraf *et al.* 2013).

### DJ-1

Mutations in the gene coding DJ-1 are associated with early onset of autosomal recessive Parkinsonism (Bonifati *et al.* 2003) and are linked to DJ-1 loss of function. DJ-1 is a 189 amino acids protein which forms a homodimer and that is expressed in all tissues including neuronal tissues (Bonifati *et al.* 2003). The precise biochemical functions of DJ-1 remain elusive, however DJ-1 has been suggested to participate in multiple pathways including the maintenance of reaction oxygen species homeostasis (Wilson 2011), regulation of gene expression (Biosa *et al.* 2017), chaperone activity (Shendelman *et al.* 2004) and the regulation of mitochondrial function (Hao *et al.* 2010). In cell models, knockdown of DJ-1 has been reported to render cells susceptible to oxidative stress (Taira *et al.* 2004). The regulation of oxidative stress by DJ-1 have been associated with DJ-1's multiple cysteine residues (C46, C53 and C106) that enable DJ-1 to sense oxidative stress by


undergoing oxidization, resulting in DJ-1 localization to the mitochondria (Canet-Avilés *et al.* 2004). The substitution of residue DJ-1's C106 with another amino acid have been reported to abrogate the protective role of DJ-1 against neuronal death in response to oxidative stress (Canet-Avilés *et al.* 2004). In addition, the structure of DJ-1 was shown to be similar to that of *Escherichia coli*'s stress response chaperone, HSP31 (Lee *et al.* 2003). Due to its structural similarity to HSP31, it has been suggested that DJ-1 may act as a chaperone that is activated in response to oxidative stress (Shendelman *et al.* 2004) and might even be involved in inhibiting  $\alpha$ -synuclein's oligomerization (Zhou *et al.* 2006; Zondler *et al.* 2014). In addition, DJ-1 has been shown to be involved in regulation of the master transcription factor, Nrf2, which is associated with oxidative stress response (Moscovitz *et al.* 2015). In response to oxidative stress DJ-1 can bind to the 20S proteasome and inhibit its activity, stabilizing partially unfolded proteins (Moscovitz *et al.* 2015). In both *Drosophila* and human dopaminergic cells, deletion of DJ-1 result in mitochondrial swelling and dysfunction, poorly coupled mitochondria and shorted lifespan. Similar defects have been reported in flies with deletion of both Parkin and PINK1, interestingly, upregulation of DJ-1 has been reported to improve the mutant phenotypes in PINK1, but not Parkin mutants, suggesting that DJ-1 is important for mitochondrial quality control and may act parallel to PINK1 (Hao *et al.* 2010; Thomas *et al.* 2010).

### LRRK2

LRRK2 is large (286 kDa) cytosolic protein with multiple functional domains which is a member of the leucine-rich repeat kinase family. LRRK2 has been shown to interact and colocalize on the outer mitochondrial membrane with multiple members of the dynamin GTPase family that modulate the mitochondrial fusion/fission mechanism, including Drp1, Mfn1, Mfn2 and OPA (Stafa *et al.* 2013). Interestingly, overexpression of LRRK2 or PD-associated mutants of LRRK2 (R1441C or G2019S) has been demonstrated to increase mitochondrial fission in primary neuron cells. The mitochondrial fragmentation induced by LRRK2 can be blocked by overexpression of a dominant negative variant of DRP1, suggesting that PD-associated mutants of LRRK2 enhance the profission function of DRP1 (Wang *et al.* 2012). Neuronal cells model that expressed the most common pathogenic mutant of LRRK2, G2019S, in cells derived from induced pluripotent stem cells (iPSC) have been reported to have increased expression of stress-response genes and  $\alpha$ -synuclein and high sensitivity to stress agents, such as hydrogen peroxide, MG-132, and 6-hydroxydopamine (Nguyen *et al.* 2011). Mutated LRRK2-G2019S has also been reported to inhibit chaperone-mediated autophagy and cause the accumulation of  $\alpha$ -synuclein, which is a known substrate

**Table 1.** Genes implicated in Parkinson's disease and involved in mitochondrial dysfunction.

Gene	Cellular function	Cellular localization	Pathways linked to cellular pathology	References
<i>DJ-1</i>	Oxidative stress sensor, chaperone	Cytosol, outer mitochondrial membrane	Mitochondrial dysfunction, oxidative stress proteasome degradation	Hao <i>et al.</i> (2010); Thomas <i>et al.</i> (2010); Wilson (2011); Shendelman <i>et al.</i> (2004)
<i>LRRK2</i>	Currently unknown. Associated with multiple pathways including: modulation of dynamin gtpases, vesicle modulation, and autophagy	Cytosol, cellular membranes	Mitochondrial dysfunction, mitochondrial morphogenesis, autophagy	Nguyen <i>et al.</i> (2011); Stafa <i>et al.</i> (2013); Wang <i>et al.</i> (2012); Orenstein <i>et al.</i> (2013)
<i>Parkin</i>	E3 ubiquitin protein ligase	Cytosol	Mitochondrial dysfunction, mitochondrial quality control, autophagy	Narendra <i>et al.</i> (2008)
<i>PINK1</i>	Mitochondria-targeted serine/threonine kinase	Outer mitochondrial membrane	Mitochondrial dysfunction, mitochondrial quality control, autophagy	Narendra <i>et al.</i> (2008); Pickrell and Youle (2015)
<i>SNCA</i>	Neurotransmitter vesicles dynamics	Cytosol, synaptic vesicles	Mitochondrial dysfunction, Lewy body formation, autophagy, Mitochondrial import, proteasome degradation	Li <i>et al.</i> (2007); Spillantini <i>et al.</i> (1997); Devi <i>et al.</i> (2008); Nakamura <i>et al.</i> (2011); Choubey <i>et al.</i> (2011); Di Maio <i>et al.</i> (2016)
<i>VPS35</i>	Retromer complex component, involved in recycling of membrane proteins	Endosomes	Mitochondrial dysfunction, autophagy, mitochondrial morphogenesis, membrane protein recycling	Tang <i>et al.</i> (2015); Wang <i>et al.</i> (2016)



**Figure 1.** Overview of potential interaction between mitochondria and  $\alpha$ -synuclein. Mitochondrial dysfunction have been shown to cause accumulation of protein misfolding in the cytosol.  $\alpha$ -synuclein may interact with the TIM/TOM mitochondrial protein import complex and inhibit its function resulting in mitochondrial dysfunction. The outer mitochondrial membrane (OMM) may interact with misfolded  $\alpha$ -synuclein resulting in membrane modeling leading to mitochondrial fission. Membrane interaction of  $\alpha$ -synuclein may also increase misfolding of  $\alpha$ -synuclein.

of the chaperone-mediated autophagy pathway (Orenstein *et al.* 2013).

### VPS35

VPS35 is a gene which belongs to a group of vacuolar protein sorting (VPS) genes which encode components of the retromer complex. The retromer complex is involved in recycling of transmembrane proteins from endosomes to the trans-Golgi network and endosomes to the plasma membrane. VPS35 has recently emerged as a gene associated with autosomal-dominant PD. The mechanisms by which mutations in VSP35 lead to pathogenesis are still unclear, however several potential mechanisms have been suggested, including impaired binding of the WASH complex and inhibition of autophagy, disruption of receptor trafficking in dendritic spines that result in altered synaptic transmission, and induction of mitochondrial fragmentation by altering the turnover of the pro-fission, DRP1 protein (Williams *et al.* 2017). VPS35-deficient mice showed impaired recycling of lysosome-associated membrane glycoprotein 2a (Lamp2a), a receptor protein thought to be involved in chaperone-mediated autophagy of  $\alpha$ -synuclein (Tang *et al.* 2015). VSP35 has also been implicated in vesicle transport between the mitochondria and peroxisomes (Braschi *et al.* 2010). In a recent study, mutation in VSP35 have been shown to increase the interaction of VPS35 with DRP1 resulting in its enhanced

turnover leading to mitochondrial fragmentation and neurodegeneration (Wang *et al.* 2016).

### Interaction of $\alpha$ -synuclein with the mitochondria

Under normal condition  $\alpha$ -synuclein is found in a soluble state in the cytosol and only weakly associates with cellular membranes: such as the endoplasmic reticulum, synaptic vesicles and mitochondrial membrane. Nevertheless, there is evidence that suggests that  $\alpha$ -synuclein (figure 1) is directly involved in mitochondrial dysfunction (Li *et al.* 2007; Devi *et al.* 2008; Nakamura *et al.* 2011). In both cultured cells and animal models over-expression of  $\alpha$ -synuclein have been shown to cause the fragmentation of the mitochondrial network (Kamp *et al.* 2010; Nakamura *et al.* 2011). Although the mechanism leading to this morphology is not yet understood, it is interesting to note that mitochondrial fragmentation appears to occur independently of Drp1, the protein responsible for mitochondrial fission in mammalian cells. Instead,  $\alpha$ -synuclein was reported to be able to alter the shape of mitochondria by directly associating with the mitochondrial membrane suggesting that  $\alpha$ -synuclein has the ability to remodel mitochondrial membranes (Nakamura *et al.* 2011, 2013). Completing these finding are studies that showed that mice expressing mutant  $\alpha$ -synuclein develop intraneuronal inclusion, mitochondrial DNA damage and fragmented mitochondria (Martin *et al.* 2006; Xie and

Chung 2012). In addition, primary neuronal cells that overexpressed mutant  $\alpha$ -synuclein, A53T, exhibited mitochondrial loss and increased mitochondrial mitophagy. Interestingly, cells in which mitochondrial fission was inhibited by the expression of a dominant negative form of the fission protein Drp1 or by overexpressing the fission protein MFN2 mitochondrial loss was not observed. Similar results were reported for cells in which mitophagy pathway was inhibited by silencing Parkin indicating that mitochondrial morphology is linked mitochondrial autophagy (Choubey *et al.* 2011). Correspondingly, it was reported that knock-down of  $\alpha$ -synuclein in *C. elegans* results in elongated mitochondria and that mitochondrial fragmentation induced by overexpression of  $\alpha$ -synuclein can be rescued by overexpression of PINK1, Parkin or DJ-1 (Kamp *et al.* 2010).

In a study conducted on a rat model, chronic exposure to rotenone, which is a complex I inhibitor that causes oxidative stress and is toxin-model for PD, caused oxidative modification and redistribution of DJ-1 to the mitochondria and downregulation of proteasome activity that resulted in the aggregation of  $\alpha$ -synuclein in both *in vivo* and *in vitro* models (Betarbet *et al.* 2006). More recently, it was reported that post-translationally dopamine modified species of  $\alpha$ -synuclein could bind to the TOM20 complex, a mitochondrial receptor complex which together with TOM22 is responsible for the recognition and import of mitochondrial proteins from the cytosol. It was reported that binding of modified  $\alpha$ -synuclein to the TOM20 complex resulted in its inability to interact with TOM22 and inhibited the import of mitochondrial protein causing a decrease in mitochondrial fidelity, loss of mitochondrial potential and an increase in reactive oxygen species in cultured cells (Di Maio *et al.* 2016). As mitochondrial targeting signals are often N-terminus amphiphilic  $\alpha$ -helices, the authors suggested that under certain conditions, the amphiphilic  $\alpha$ -helix located in the N-terminus of  $\alpha$ -synuclein can interact and interfere with the TOM20 complex. Interestingly, it was reported that only small molecular weight oligomeric species but not monomeric or fibrillar forms of dopamine modified  $\alpha$ -synuclein were cytotoxic. This point is also sustained by previous studies that showed that catecholamines related to dopamine can inhibit synuclein fibrillization therefore suggesting an explanation as to why dopaminergic neurons are more susceptible to damage in PD.

Regarding  $\alpha$ -synuclein's involvement in the processing of mitochondrial protein, it is interesting to note that recently other multiple studies have linked proteostatic stress to mitochondrial dysfunction. A study recently published in yeast cells showed that protein aggregates that form in the cytosol under stress interact with the mitochondrial import complex and molecular chaperones such as Hsp104 to enter the mitochondria via import receptors such as Tom70 followed by degradation by mitochondrial proteases. In addition, blocking mitochondrial import

appeared to prevent the dissolution of aggregates. These findings suggest a protective role for mitochondria by maintaining cytosolic proteostasis (Conway *et al.* 2001). Another study done in yeast showed that in response to mitochondrial dysfunction and inefficient mitochondrial protein import can lead to cytotoxic accumulation of mitochondrial proteins that results in protein aggregation, subsequently leading to cellular degeneration (Ruan *et al.* 2017).

Several other potential mechanisms have been suggested that link  $\alpha$ -synuclein to mitochondrial dysfunction and should be considered: Peroxisome proliferator-activated receptor  $\gamma$  coactivator 1 $\alpha$  (PGC-1 $\alpha$ ), is a master regulator of mitochondrial biogenesis and mitochondrial energy metabolism that has been reported to be downregulated in human PD brain as well in transgenic animal model and cultured cell expressing mutant  $\alpha$ -synuclein (A30P). Correspondingly, downregulation of PGC-1 $\alpha$  in cell culture neurons and PGC-1 $\alpha$  deficient mice resulted in induction of cytotoxic  $\alpha$ -synuclein oligomerization (Zheng *et al.* 2010). Other studies have suggested that  $\alpha$ -synuclein might have a role in disrupting the mitochondria-associated endoplasmic reticulum membrane (MAM) subdomain. The MAM subdomain tethers mitochondria to the surface of the endoplasmic reticulum by a set of proteins that bridge the outer mitochondrial membrane to the endoplasmic reticulum membrane. The MAM domain is associated with regulating several fundamental cellular processes such as mitochondrial biogenesis, mitochondrial fission and fusion, and calcium buffering (Paillusson *et al.* 2016). Moreover, tau (microtubule-associated protein tau) has been shown to interact with  $\alpha$ -synuclein and their interaction may lead to the aggregation of both proteins. For this reason,  $\alpha$ -synuclein oligomers have been suggested to impair axonal transport machinery by decreasing microtubule stability (Oikawa *et al.* 2016).

## Concluding remarks

In addition to providing most of the cellular ATP, mitochondria also play a central role in a wide variety of metabolic pathways and cellular functions. As a result, disruption of mitochondrial homeostasis may lead to cellular dysfunction and cell death. In this review, we have discussed different aspects of two major pathological hallmarks of PD: mitochondrial dysfunction and protein aggregation. These two seemingly unrelated responses to stress have had mounting genetic and biochemical evidence over the last two decades that linked them to PD. However, it is only recently that possible functional links between the aggregation of  $\alpha$ -synuclein and mitochondrial function have come to light. Future studies will have to explore the molecular mechanisms that involve  $\alpha$ -synuclein and mitochondria interaction and different pathways that

relate the both mitochondrial dysfunction and protein quality control.

## References

- Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W. H., Castillo P. E. *et al.* 2000 Mice lacking  $\alpha$ -synuclein display functional deficits in the nigrostriatal dopamine system. *Neuron* **25**, 239–252.
- Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., Sherman H., Yu L., Shah B. *et al.* 2013 Alpha-synuclein p. H50Q a novel pathogenic mutation for Parkinson's disease. *Mov. Disord.* **28**, 811–813.
- Bendor J. T., Logan T. P. and Edwards R. 2013 The function of  $\alpha$ -synuclein. *Neuron* **79**, 1044–1066.
- Bertholet A. M., Delerue T., Millet A. M., Moulis M. F., David C., Daloyau M. *et al.* 2016 Mitochondrial fusion/fission dynamics in neurodegeneration and neuronal plasticity. *Neurobiol. Dis.* **90**, 3–19.
- Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. 2000 Chronic systemic pesticide exposure reproduces features of Parkinson's disease. *Nature Neurosci.* **3**, 1301.
- Betarbet R., Canet-Aviles R. M., Sherer T. B., Mastroberardino P. G., McLendon C., Kim J. H. *et al.* 2006 Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1  $\alpha$ -synuclein and the ubiquitin-proteasome system. *Neurobiol. Dis.* **22**, 404–420.
- Biosa A., Sandrelli F., Beltramini M., Greggio E., Bubacco L. and Bisaglia M. 2017 Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease. *Neurobiol. Dis.* **108**, 65–72.
- Bonifati V., Rizzu P., Van Baren M. J., Schaap O., Breedveld G. J. *et al.* 2003 Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* **299**, 256–259.
- Braschi E., Goyon V., Zunino R., Mohanty A., Xu L. and McBride H. M. 2010 Vps35 mediates vesicle transport between the mitochondria and peroxisomes. *Curr. Biol.* **20**, 1310–1315.
- Breydo L., Wu J. W. and Uversky V. N. 2012  $\alpha$ -Synuclein misfolding and Parkinson's disease. *Biochim. Biophys. Acta* **1822**, 261–285.
- Brielle S., Gura R. and Kaganovich D. 2015 Imaging stress. *Cell Stress Chaperones* **20**, 867–874.
- Burré J. 2015 The synaptic function of  $\alpha$ -synuclein. *J. Parkinson Dis.* **5**, 699–713.
- Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R. and Südhof T. C. 2010  $\alpha$ -Synuclein promotes SNARE-complex assembly in vivo and in vitro. *Science* **329**, 1663–1667.
- Burté F., Carelli V., Chinnery P. F. and Yu-Wai-Man P. 2015 Disturbed mitochondrial dynamics and neurodegenerative disorders. *Nature Rev. Neurol.* **11**, 11.
- Cabin D. E., Shimazu K., Murphy D., Cole N. B., Gottschalk W., McIlwain K. L. *et al.* 2002 Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking  $\alpha$ -synuclein. *J. Neurosci.* **22**, 8797–8807.
- Canet-Aviles R. M., Wilson M. A., Miller D. W., Ahmad R., McLendon C. Bandyopadhyay S. *et al.* 2004 The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. *Proc. Natl. Acad. Sci. USA* **101**, 9103–9108.
- Chan N. C., Salazar A. M., Pham A. H., Sweredoski M. J., Kolawa N. J., Graham R. L. *et al.* 2011 Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum. Mol. Genet.* **20**, 1726–1737.
- Chen H., Detmer S. A., Ewald A. J., Griffin E. E., Fraser S. E. and Chan D. C. 2003 Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J. Cell Biol.* **160**, 189–200.
- Cheng H. C., Ulane C. M. and Burke R. E. 2010 Clinical progression in Parkinson disease and the neurobiology of axons. *Ann. Neurol.* **67**, 715–725.
- Choubey V., Safulina D., Vaarmann A., Cagalinec M., Wareski P., Kuum M. *et al.* 2011 Mutant A53T  $\alpha$ -synuclein induces neuronal death by increasing mitochondrial autophagy. *J. Biol. Chem.* **286**, 10814–10824.
- Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. 2000 Acceleration of oligomerization not fibrillization is a shared property of both  $\alpha$ -synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. *Proc. Natl. Acad. Sci. USA* **97**, 571–576.
- Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. 2001 Kinetic stabilization of the  $\alpha$ -synuclein protofibril by a dopamine- $\alpha$ -synuclein adduct. *Science* **294**, 1346–1349.
- Cremades N., Cohen S. I., Deas E., Abramov A. Y., Chen A. Y., Orte A. *et al.* 2012 Direct observation of the interconversion of normal and toxic forms of  $\alpha$ -synuclein. *Cell* **149**, 1048–1059.
- Dauer W. and Przedborski S. 2003 Parkinson's disease: mechanisms and models. *Neuron* **39**, 889–909.
- Davidson W. S., Jonas A., Clayton D. F. and George J. M. 1998 Stabilization of  $\alpha$ -synuclein secondary structure upon binding to synthetic membranes. *J. Biol. Chem.* **273**, 9443–9449.
- Desplats P., Lee H. J., Bae E. J., Patrick C., Rockenstein E., Crews L. *et al.* 2009 Inclusion formation and neuronal cell death through neuron-to-neuron transmission of  $\alpha$ -synuclein. *Proc. Natl. Acad. Sci. USA* **106**, 13010–13015.
- Devi L., Raghavendran V., Prabhu B. M., Avadhani N. G. and Anandatheerthavarada H. K. 2008 Mitochondrial import and accumulation of  $\alpha$ -synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. *J. Biol. Chem.* **283**, 9089–9100.
- Di Maio R., Barrett P. J., Hoffman E. K., Barrett C. W., Zharikov A., Borah A. *et al.* 2016  $\alpha$ -Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. *Sci. Transl. Med.* **8**, 342ra78–342ra78.
- Dijkstra A. A., Voorn P., Berendse H. W., Groenewegen H. J., Rozemuller A. J. and Berg W. D. 2014 Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. *Mov. Disord.* **29**, 1244–1251.
- Drin G. and Antony B. 2010 Amphipathic helices and membrane curvature. *FEBS Lett.* **584**, 1840–1847.
- Eliezer D., Kutluay E., Bussell Jr R. and Browne G. 2001 Conformational properties of  $\alpha$ -synuclein in its free and lipid-associated states I. *J. Mol. Biol.* **307**, 1061–1073.
- Farrer M., Vrieze W. D., Crook R., Boles L., Perez-Tur J., Hardy J. *et al.* 1998 Low frequency of  $\alpha$ -synuclein mutations in familial Parkinson's disease. *Ann. Neurol.* **43**, 394–397.
- Farrer M., Kachergus J., Forno L., Lincoln S., Wang D. S., Hulihan M. *et al.* 2004 Comparison of kindreds with parkinsonism and  $\alpha$ -synuclein genomic multiplications. *Ann. Neurol.* **55**, 174–179.
- Farrer M. J. 2006 Genetics of Parkinson disease: paradigm shifts and future prospects. *Nat. Rev. Genet.* **7**, 306.
- Feany M. B. and Bender W. W. 2000 A Drosophila model of Parkinson's disease. *Nature* **404**, 394.
- Giasson B. I., Murray I. V., Trojanowski J. Q. and Lee V. M. Y. 2001 A hydrophobic stretch of 12 amino acid residues in the middle of  $\alpha$ -synuclein is essential for filament assembly. *J. Biol. Chem.* **276**, 2380–2386.

- Hao L. Y., Giasson B. I. and Bonini N. M. 2010 DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. *Proc. Natl. Acad. Sci. USA* **107**, 9747–9752.
- Hollenbeck P. J. 2005. Mitochondria and neurotransmission: evacuating the synapse. *Neuron* **47**, 331–333.
- Jin S. M., Lazarou M., Wang C., Kane L. A., Narendra D. P. and Youle R. J. 2010 Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J. Cell Biol.* **191**, 933–942.
- Jo E., McLaurin J., Yip C. M., George-Hyslop P. S. and Fraser P. E. 2000  $\alpha$ -Synuclein membrane interactions and lipid specificity. *J. Biol. Chem.* **275**, 34328–34334.
- Johnson J., Hague S. M., Hanson M., Gibson A., Wilson K. E., Evans E. W. *et al.* 2004 SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. *Neurology* **63**, 554–556.
- Kaganovich D. 2017 There is an inclusion for that: material properties of protein granules provide a platform for building diverse cellular functions. *Trends Biochem. Sci.* **42**, 765–776.
- Kaganovich D., Kopito R. and Frydman J. 2008 Misfolded proteins partition between two distinct quality control compartments. *Nature* **454**, 1088.
- Kamp F., Exner N., Lutz A. K., Wender N., Hegermann J., Brunner B. *et al.* 2010 Inhibition of mitochondrial fusion by  $\alpha$ -synuclein is rescued by PINK1 Parkin and DJ-1. *EMBO J.* **29**, 3571–3589.
- Kann O. and Kovács R. 2007 Mitochondria and neuronal activity. *Am. J. Physiol. Cell Physiol.* **292**, C641–C657.
- Khandelia H., Ipsen J. H. and Mouritsen O. G. 2008 The impact of peptides on lipid membranes. *Biochim. Biophys. Acta.* **1778**, 1528–1536.
- Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M. Sigfried K. *et al.* 1998 AlaSOPro mutation in the gene encoding  $\alpha$ -synuclein in Parkinson's disease. *Nat. Genet.* **18**, 101–108.
- Kuwahara T., Koyama A., Gengyo-Ando K., Masuda M., Kowa H., Tsunoda M. *et al.* 2006 Familial Parkinson mutant  $\alpha$ -synuclein causes dopamine neuron dysfunction in transgenic *Caenorhabditis elegans*. *J. Biol. Chem.* **281**, 334–340.
- Langston J. W., Ballard P., Tetrud J. W. and Irwin I. 1983 Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* **219**, 979–980.
- Lashuel H. A., Overk C. R., Oueslati A. and Masliah E. 2013 The many faces of  $\alpha$ -synuclein: from structure and toxicity to therapeutic target. *Nat. Rev. Neurosci.* **14**, 38.
- Lázaro D. F., Rodrigues E. F., Langohr R., Shahpasandzadeh H., Ribeiro T., Guerreiro P. *et al.* 2014 Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. *PLoS Genet.* **10**, e1004741.
- Lee S. J., Kim S. J., Kim I. K., Ko J., Jeong C. S., Kim *et al.* 2003 Crystal structures of human DJ-1 and Escherichia coli Hsp31 which share an evolutionarily conserved domain. *J. Biol. Chem.* **278**, 44552–44559.
- Lesage S., Anheim M., Letournel F., Bousset L., Honoré A., Rozas N. *et al.* 2013 G51D  $\alpha$ -synuclein mutation causes a novel Parkinsonian–pyramidal syndrome. *Ann. Neurol.* **73**, 459–471.
- Li W. W., Yang R., Guo J. C., Ren H. M., Zha X. L., Chen *et al.* 2007 Localization of  $\alpha$ -synuclein to mitochondria within mid-brain of mice. *Neuroreport* **18**, 1543–1546.
- Lin M. T. and Beal M. F. 2006 Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature* **443**, 787.
- Martin L. J., Pan Y., Price A. C., Sterling W., Copeland N. G., Jenkins *et al.* 2006 Parkinson's disease  $\alpha$ -synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. *J. Neurosci.* **26**, 41–50.
- Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A. *et al.* 2000 Dopaminergic loss and inclusion body formation in  $\alpha$ -synuclein mice: implications for neurodegenerative disorders. *Science* **287**, 1265–1269.
- Michel P. P., Hirsch E. C. and Hunot S. 2016 Understanding dopaminergic cell death pathways in Parkinson disease. *Neuron* **90**, 675–691.
- Moscovitz O., Ben-Nissan G., Fainer I., Pollack D., Mizrachi L. and Sharon M. 2015 The Parkinson's-associated protein DJ-1 regulates the 20S proteasome. *Nat. Commun.* **6**, 6609.
- Murphy D. D., Rueter S. M., Trojanowski J. Q. and Lee V. M. Y. 2000 Synucleins are developmentally expressed and  $\alpha$ -synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. *J. Neurosci.* **20**, 3214–3220.
- Nakamura K. 2013  $\alpha$ -Synuclein and mitochondria: partners in crime? *Neurotherapeutics* **10**, 391–399.
- Nakamura K., Nemani V. M., Azarbal F., Skibinski G., Levy J. M., Egami K. *et al.* 2011 Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein  $\alpha$ -synuclein. *J. Biol. Chem.* **286**, 20710–20726.
- Narendra D., Tanaka A., Suen D. F. and Youle R. J. 2008 Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J. Cell Biol.* **183**, 795–803.
- Nemani V. M., Lu W., Berge V., Nakamura K., Onoa B., Lee M. K. *et al.* 2010 Increased expression of  $\alpha$ -synuclein reduces neurotransmitter release by inhibiting synaptic vesicle recluster after endocytosis. *Neuron* **65**, 66–79.
- Nguyen H. N., Byers B., Cord B., Shcheglovitov A., Byrne J., Gujar P. *et al.* 2011 LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell* **8**, 267–280.
- Nicklas W. J., Youngster S. K., Kindt M. V. and Heikkila R. E. 1987 IV. MPTP MPP+ and mitochondrial function. *Life Sci.* **40**, 721–729.
- Nussbaum R. L. 2017 The identification of alpha-synuclein as the first Parkinson disease gene. *J. Parkinsons Dis.* **7**(s1), S43–S49.
- Oikawa T., Nonaka T., Terada M., Tamaoka A., Hisanaga S. I. and Hasegawa M. 2016  $\alpha$ -Synuclein fibrils exhibit gain of toxic function promoting tau aggregation and inhibiting microtubule assembly. *J. Biol. Chem.* **291**, 15046–15056.
- Orenstein S. J., Kuo S. H., Tasset I., Arias E., Koga H., Fernandez-Carasa I. *et al.* 2013 Interplay of LRRK2 with chaperone-mediated autophagy. *Nat. Neurosci.* **16**, 394.
- Paillusson S., Stoica R., Gomez-Suaga P., Lau D. H., Mueller S., Miller T. *et al.* 2016 There's something wrong with my MAM; the ER–mitochondria axis and neurodegenerative diseases. *Trends Neurosci.* **39**, 146–157.
- Payton J. E., Perrin R. J., Woods W. S. and George J. M. 2004 Structural determinants of PLD2 inhibition by  $\alpha$ -synuclein. *J. Mol. Biol.* **337**, 1001–1009.
- Pickrell A. M. and Youle R. J. 2015 The roles of PINK1 parkin and mitochondrial fidelity in Parkinson's disease. *Neuron* **85**, 257–273.
- Pineda A. and Burré J. 2017 Modulating membrane binding of  $\alpha$ -synuclein as a therapeutic strategy. *Proc. Nat. Acad. Sci. USA* **114**, 1223–1225.
- Poewe W., Seppi K., Tanner C. M., Halliday G. M., Brundin P., Volkman J. *et al.* 2017 Parkinson disease. *Nat. Rev. Dis. Primers* **3**, 17013.
- Polymeropoulos M. H., Higgins J. J., Golbe L. I., Johnson W. G., Ide S. E., Di Iorio *et al.* 1996 Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. *Science* **274**, 1197–1199.
- Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A. *et al.* 1997 Mutation in the  $\alpha$ -synuclein gene identified in families with Parkinson's disease. *Science* **276**, 2045–2047.
- Poole A. C., Thomas R. E., Andrews L. A., McBride H. M., Whitworth A. J. and Pallanck L. J. 2008 The PINK1/Parkin

- pathway regulates mitochondrial morphology. *Proc. Nat. Acad. Sci. USA* **105**, 1638–1643.
- Ruan L., Zhou C., Jin E., Kucharavy A., Zhang Y., Wen Z. *et al.* 2017 Cytosolic proteostasis through importing of misfolded proteins into mitochondria. *Nature* **543**, 443.
- Sarraf S. A., Raman M., Guarani-Pereira V., Sowa M. E., Huttlin E. L., Gygi S. P. *et al.* 2013 Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. *Nature* **496**, 372.
- Schrepfer E. and Scorrano L. 2016 Mitofusins from mitochondria to metabolism. *Mol. Cell* **61**, 683–694.
- Shendelman S., Jonason A., Martinat C., Leete T. and Abeliovich A. 2004 DJ-1 is a redox-dependent molecular chaperone that inhibits  $\alpha$ -synuclein aggregate formation. *PLoS Biol.* **2**, p.e362.
- Singleton A. B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus et al. 2003  $\alpha$ -Synuclein locus triplication causes Parkinson's disease. *Science* **302**, 841.
- Smirnova E., Shurland D. L., Ryazantsev S. N. and van der Bliek A. M. 1998 A human dynamin-related protein controls the distribution of mitochondria. *J. Cell Biol.* **143**, 351–358.
- Spillantini M. G., Schmidt M. L., Lee V. M. Y., Trojanowski J. Q., Jakes R. and Goedert M. 1997  $\alpha$ -Synuclein in Lewy bodies. *Nature* **388**, 839.
- Stafa K., Tsika E., Moser R., Musso A., Glauser L., Jones A. *et al.* 2013 Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. *Hum. Mol. Genet.* **23**, 2055–2077.
- Taira T., Saito Y., Niki T., Iguchi-Arigo S. M., Takahashi K. and Ariga H. 2004 DJ-1 has a role in antioxidative stress to prevent cell death. *EMBO Rep.* **5**, 213–218.
- Tanaka M., Kim Y. M., Lee G., Junn E., Iwatsubo T. and Mouradian M. M. 2004 Aggresomes formed by  $\alpha$ -synuclein and synphilin-1 are cytoprotective. *J. Biol. Chem.* **279**, 4625–4631.
- Tang F. L., Erion J. R., Tian Y., Liu W., Yin D. M., Ye J. *et al.* 2015 VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a a receptor of chaperone-mediated autophagy that is critical for  $\alpha$ -synuclein degradation and prevention of pathogenesis of Parkinson's disease. *J. Neurosci.* **35**, 10613–10628.
- Thomas K. J., McCoy M. K., Blackinton J., Beilina A., van der Brug M., Sandebring A. *et al.* 2010 DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. *Hum. Mol. Genet.* **20**, 40–50.
- Trinh J. and Farrer M. 2013 Advances in the genetics of Parkinson disease. *Nat. Rev. Neurol.* **9**, 445.
- Ulmer T. S., Bax A., Cole N. B. and Nussbaum R. L. 2005 Structure and dynamics of micelle-bound human  $\alpha$ -synuclein. *J. Biol. Chem.* **280**, 9595–9603.
- Uversky V. N. 2007 Neuropathology biochemistry and biophysics of  $\alpha$ -synuclein aggregation. *J. Neurochem.* **103**, 17–37.
- Wang W., Wang X., Fujioka H., Hoppel C., Whone A. L., Caldwell M. A. 2016 Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. *Nat. Med.* **22**, 54.
- Wang X., Yan M. H., Fujioka H., Liu J., Wilson-Delfosse A., Chen S. G. *et al.* 2012 LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. *Hum. Mol. Genet.* **21**, 1931–1944.
- Westermann B. 2010 Mitochondrial fusion and fission in cell life and death. *Nat. Rev. Mol. Cell Biol.* **11**, 872.
- Williams E. T., Chen X. and Moore D. J. 2017 VPS35 the retromer complex and Parkinson's disease. *J. Parkinsons Dis.* **7**, 219–233.
- Wilson M. A. 2011 The role of cysteine oxidation in DJ-1 function and dysfunction. *Antioxid. Redox Signal.* **15**, 111–122.
- Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M. and Biere A. L. 1999  $\alpha$ -Synuclein fibrillogenesis is nucleation-dependent implications for the pathogenesis of Parkinson's disease. *J. Biol. Chem.* **274**, 19509–19512.
- Xie W. and Chung K. K. 2012 Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. *J. Neurochem.* **122**, 404–414.
- Yamano K. and Youle R. J. 2013 PINK1 is degraded through the N-end rule pathway. *Autophagy* **9**, 1758–1769.
- Zarranz J. J., Alegre J., Gómez-Esteban J. C., Lezcano E., Ros R., Ampuero I. *et al.* 2004 The new mutation E46K of  $\alpha$ -synuclein causes parkinson and Lewy body dementia. *Ann. Neurol.* **55**, 164–173.
- Zheng B., Liao Z., Locascio J. J., Lesniak K. A., Roderick S. S., Watt M. L. *et al.* 2010 PGC-1 $\alpha$  a potential therapeutic target for early intervention in Parkinson's disease. *Sci. Transl. Med.* **2**, 52ra73–52ra73.
- Zhou W., Zhu M., Wilson M. A., Petsko G. A. and Fink A. L. 2006 The oxidation state of DJ-1 regulates its chaperone activity toward  $\alpha$ -synuclein. *J. Mol. Biol.* **356**, 1036–1048.
- Zonder L., Miller-Fleming L., Repici M., Gonçalves S., Tenreiro S., Rosado-Ramos R. *et al.* 2014 DJ-1 interactions with  $\alpha$ -synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. *Cell Death Dis.* **5**, e1350.